Covid variants are mutating and are still
a global threat, irrespective of the type of variant and its replication
potential, the cytokine storm, which needs to be addressed with promptness
contributes to the ultimate severe illness. Now, this cytokine storm is
characterized by the abnormal release of circulating cytokines causing adverse
reactions.

The study that I am talking about
aimed to evaluate the effect of itolizumab on clinical outcomes of patients
with moderate-severe COVID-19 disease admitted to ICU. The primary aim of the
current study is to find out any mortality benefit in 14 days while the
secondary aim was to assess the morbidity outcomes in terms of reduction in
inflammatory markers and also the duration of hospital stays.

A retrospective case-control study included
a total of 62 patients. Out of which 31 patients received itolizumab and 31
patients didn’t receive itolizumab (designated as controls).

Among the total patients recruited, 68% of the
study population was male and 32% were female. A total of 12 patients expired
among cases and 13 expired among controls. So the results showed that the overall
mortality in both groups was noted to be almost similar. There was also a
significant reduction in inflammatory markers, like interleukins-6 (IL-6) and
D-dimer in cases compared to the control group.

Hence,
the researchers concluded that treating patients with cytokine storms before
they require intubation/mechanical ventilation is crucial to preventing deaths.
Itolizumab has shown no clinical benefit in critically ill COVID-19 patients,
however, timely initiation of itolizumab therapy may serve as a key therapeutic
option in preventing the mortality and morbidity outcomes in moderate-severe
COVID-19 patients.

Reference:

Kurri N, Tyagi
B, Kaushik A, et al. Role of Itolizumab in the Treatment of COVID-19 Patients,
Admitted to ICU at a Tertiary Care Hospital. J Assoc Physicians India
2022;70(10):35–38.

Leave a Reply

Your email address will not be published. Required fields are marked *